21st Oct 2013 09:13
LONDON (Alliance News) - Tissue Regenix Group PLC said Monday that its DermaPure healing treatment had completely healed 60% of patients with chronic wounds in a clinical trial undertaken by the University Hospital of South Manchester. DermaPure had produced an 87% reduction in the size of wounds on patients in the trial, Tissue Regenix said.
The company said the treatment could be administered in hospitals and GP clinics.
DermaPure works using a decellularisation process that removes cells from human skin and allows it to be used as a patch over open wounds in a single application. This then acts as a scaffold to kick start the healing process and regenerate living skin tissue. It requires no anaesthetic and can be stored at room temperature, the company said.
DermaPure will launch in the US in the first half of 2014.
Shares in Tissue Regenix were trading up 4.3% at 11.60 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group